ABSTRACT
Hyperinsulinemic hypoglycemia may occur in various settings, such as exogenous insulin administration, insulin secretagogue intoxication, insulinoma or other b cell pathologies, or autoimmune hypoglycemia syndrome (AHS), which comprises the presence of insulin autoimmune syndrome (IAS) as well as antibodies against insulin receptor. AHS is characterized by the presence of anti-insulin receptor antibodies or anti-insulin antibodies in individuals without prior exposure to exogenous insulin and has been rarely described in the non-Asian population. 1 Hypoglycemia is the major symptom that brings patients with IAS to medical attention. The unregulated liberation of insulin from a large pool of circulating insulin-antibody complex is thought to produce sporadic hypoglycemia during both fasting and postprandial states. Such a mechanism has been proposed to explain prolonged episodes of hypoglycemia in certain insulin-treated diabetic patients. Although severe, IAS hypoglycemia usually resolves spontaneously within a few weeks or months, especially in Asian patients. Due to the patient's insulin antibodies that interfere with the insulin immunoassay, insulin levels during hypoglycemic episodes may appear excessively elevated. This increase in insulin level could falsely suggest the presence of an insulinoma, which potentially could lead to unnecessary surgery. 2 In this article, we report the rare presentation of a white man with autoimmune hypoglycemia having excessively elevated insulin, proinsulin, and C-peptide levels. Positive anti-insulin antibodies ultimately confirmed IAS. We comment on the utility of measuring free C-peptide levels to differentiate IAS from insulinoma or other causes of endogenous hyperinsulinism. Finally, we recommend free C-peptide as a useful assay for characterizing IAS due to autoantibodies to insulin resulting in an increase in total C-peptide levels. 
Case Report
A 64-year-old white man with hypertension, anti-thyroid peroxidase antibody-negative primary hypothyroidism, and a history of alcohol abuse was seen in the clinic for 2 months for fasting and postprandial shakiness, confusion, and syncope. He had no personal history of gastric bypass surgery or family history of endocrine or autoimmune disorders and denied nonprescription drug or supplement use, prior insulin or antihyperglycemic medication ingestion or access, or recent exposure to antibiotics or thiol medications. His medications included clonidine, simvastatin, levothyroxine, terazosin, folate, and thiamine.
Fasting laboratory tests revealed a serum glucose of 34 mg/dL, and the patient was admitted to the hospital for further workup. Concurrent insulin level was elevated at 1,400 µIU/mL (reference range, 3.3-22.1 µIU/mL), with a total C-peptide level of 31.2 ng/mL (reference range, 1.1-4.4 ng/mL). Physical examination did not reveal features of hypopituitarism, acanthosis nigricans, or skin tags.
Minutes after arrival, the patient became confused and diaphoretic, exhibiting slurred speech and inappropriate eye movements. Fingerstick blood glucose was 39 mg/dL, corrected to 168 mg/dL with resolution of the patient's symptoms after oral glucose and initiation of intravenous dextrose and fluids. Computed tomography (CT) of the abdomen/pelvis with contrast was negative for enhancing pancreatic masses, right upper quadrant abdominal ultrasound was unremarkable, and brain magnetic resonance imaging (MRI) showed no discrete pituitary or other intracranial abnormality. Salient laboratory findings are summarized in ❚Table 1❚.
The patient was maintained on 10% intravenous dextrose, verapamil, and diazoxide; however, fingerstick blood glucose measurements continued to demonstrate one to three episodes of fasting and nonfasting hypoglycemia daily (particularly tending to occur between 4:00 and 6:00 am). Laboratory tests during one such episode revealed a serum blood glucose of 43 mg/dL and an insulin level of more than 1,400 µIU/mL (reference range, 3.3-22.1 µIU/mL), with an elevated total C-peptide of 31.2 ng/mL and a proinsulin level of 3,954 pmol/L (reference range, 0.0-10.0 pmol/L) ( Table 1) .
Sulfonylurea screens, repeated on two occasions, were negative (Table 1) . Endoscopic ultrasound showed a heterogeneous-appearing pancreas consistent with the patient's alcohol abuse, with a biopsy specimen of a 4.5-mm ill-defined nodule demonstrating only benign pancreatic acinar cells. Given the patient's excessively high insulin levels, dilution studies were undertaken to assess for interference in the insulin immunoassay. Serum was diluted in 1/10, 1/20, and 1/40 with assay diluent. Absolute insulin levels failed to dilute linearly (141.0, 200.5, and 261.0 µIU/ mL with increasing dilutions, respectively), suggesting an interfering substance in the patient's serum. Given the clinical presentation of hypoglycemia with increased insulin levels, negative imaging, and evidence of antibody interference, a diagnosis of autoimmune hypoglycemia due to anti-insulin antibodies was entertained, and samples were sent to the reference laboratory for anti-insulin antibodies. Autoimmune type B insulin resistance (due to anti-insulin receptor antibodies) was ruled out by the patient's white race and lack of acanthosis nigricans (present in 92% of patients with type B, according to the National Institutes of Health series 1 ) or clinical or biochemical evidence of systemic lupus erythematosus. Further testing for anti-insulin antibodies revealed a very high level of 2,809 µU/mL (reference range, <5.0 µU/mL; Esoterix, Calabasas Hills, CA). A sample was sent to another reference laboratory (ARUP, Salt Lake City, UT), which also confirmed elevated anti-insulin antibodies at more than 50 U/mL (reference range, 0.0-0.4 U/mL). Serum protein electrophoresis demonstrated an abnormal monoclonal protein in the g region at 0.1 g/dL (characterized by serum immunofixation as IgG k), although k/l free light chains and urine protein electrophoresis were normal, and serum total protein was low at 6.2 g/dL (reference range, 6.5-8.1 g/dL). There were no other features consistent with multiple myeloma.
Because the patient had very high immunoreactive insulin, proinsulin, and C-peptide levels, free C-peptide was assayed following polyethylene glycol (PEG) precipitation per the method of Nakagawa et al 3 and Kuzuya et al 4 to rule out endogenous hyperinsulinism. 5 Briefly, 25% PEG-6000 (Sigma, St Louis, MO) was added to an equal volume of chilled plasma. The sample was vigorously vortexed and then spun at 3,000 rpm for 45 minutes in a refrigerated centrifuge. 4 Thereafter C-peptide was assayed in the supernatants using an enzyme-linked immunosorbent assay from Mercodia (Uppsala, Sweden), which has a total precision of 7.6%. Precipitation of two frozen serum samples from the patient with 25% PEG yielded a mean free C-peptide level of 3.1 ng/mL (within the reference range, 1.1-4.4 ng/mL) with an elevated total C-peptide level of 9.5 ng/mL. Samples run on two healthy controls yielded a 97% recovery of C-peptide levels with precipitation, showing mean free and total C-peptide values to be within the reference range (2.8 and 2.9 ng/mL, respectively). Assaying high and low Mercodia assay controls with and without 25% PEG treatment also demonstrated all values within manufacturer-reported target ranges. Since PEG precipitation did not interfere with normal volunteer or control measurements, the assay proved a valid measure of free C-peptide. The patient's normal free C-peptide excluded a b cell source for the elevated insulin, proinsulin, and C-peptide levels, supporting interference accounting for an elevated C-peptide (and likely proinsulin). 1, 5, 6 Total and PEG-treated insulin levels were similarly assayed in pooled plasma from three samples. The total insulin level was 1,677 µIU/mL, whereas the free insulin level following PEG precipitation was 143.8 µIU/mL, or 8.6% of the total value. Nonetheless, free insulin, unlike free C-peptide, was elevated, explaining hypoglycemia due to release from the insulin-antibody complex.
The patient was begun on a low-carbohydrate diet, acarbose, and oral prednisone 75 to 100 mg/d, but hypoglycemia persisted. Glucagon therapy was also ineffective. Therefore, the patient underwent three sessions of plasmapheresis, after which time repeat anti-insulin antibody remained high at more than 50.0 U/mL (reference range, <0.4 U/mL; ARUP), but insulin and proinsulin levels were improved at 85.1 µIU/mL (reference range, 3.3-22.1 µIU/mL) and 333.0 pmol/L (reference range, 0-10.0 pmol/L), respectively (Table 1) . His blood glucose improved to the high 60s mg/dL, and his neuroglycopenic symptoms resolved. He was discharged home on prednisone 80 mg each morning and 20 mg each evening; a low-carbohydrate diet with multiple small, frequent snacks/meals; acarbose 50 mg/d with meals; and verapamil (240 mg/d).
On close follow-up, the patient was doing well without further hypoglycemia but became cushingoid. His oral prednisone dose was tapered to 60 mg/d. Laboratory results showed a fasting glucose level of 81 mg/dL, with an insulin level that increased again to more than 1,000.0 µIU/mL (reference range, 3.3-22.1 µIU/mL), a proinsulin level of 5,400.6 pmol/L (0.0-10.0 pmol/L), a C-peptide level of 108.2 ng/mL (1.1-4.4 ng/mL, confirmed on dilution), and an antiinsulin antibody level of 2,070 µU/mL (negative <5.0 µU/ mL). Again, a small 0.1-g/dL monoclonal IgG k M-protein was observed, and thyroid-stimulating hormone was 1.15 µIU/mL (Table 1) .
Blood glucose measurements revealed no hypoglycemic levels, with testing four times a day even showing frequent postprandial hyperglycemia (blood glucose measurements to the 200s-300s mg/dL) throughout the day. However, the patient was found deceased in his home several days after his follow-up clinic visit. Official cause of death per the coroner was hypertension, although autopsy was declined. No evidence of alcohol or illicit drug abuse was reported.
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© American Society for Clinical Pathology Discussion IAS, due to autoantibodies to insulin, or Hirata disease is the third leading cause of spontaneous hypoglycemia in Japan but remains an extremely rare clinical entity, especially in nonAsian populations. [5] [6] [7] [8] [9] IAS is characterized by hypoglycemia and hyperinsulinemia due to anti-insulin antibodies in patients without prior exposure to exogenous insulin. [5] [6] [7] [8] [9] Since its first description in 1970, 8 only around 380 cases of IAS have been reported in the medical literature as of 2014, with less than 15% of these cases described in non-Japanese populations. However, this disorder, while rare in non-Asian populations, has been reported in 58 white patients, as reviewed by Lupsa et al. 1 The pathogenesis of the hypoglycemia has not been precisely elucidated, but it has been speculated that the antibody binds and releases insulin out of synchrony with ambient blood glucose level. 1 The need to measure anti-insulin antibodies during hypoglycemia workup is debated, because IAS occurs so rarely in the United States. 5 But in patients with extraordinarily high measured levels of total insulin, artifactual elevation (in a conventional insulin immunoassay) caused by antiinsulin antibodies should be considered to avoid unnecessary surgical intervention in these patients for whom conservative therapy, coupled with immunosuppression, is generally the best treatment. 1, 9 In this report, we describe a white man with symptomatic hypoglycemia who, on investigation, had an excessively elevated total insulin level (>100 µIU/mL) with elevated total proinsulin and C-peptide levels. Since insulinoma is the most common cause of endogenous hyperinsulinemic hypoglycemia, this was the initial diagnosis, and the patient was subjected to multiple procedures, including CT, MRI, ultrasound, and endoscopic ultrasound with pancreatic biopsy. However, imaging studies did not confirm a diagnosis of insulinoma. Based on the very high levels of insulin (>100 µIU/mL) and the dilution studies showing that there was no decrease in levels with increasing dilutions, antibody interference was entertained. Since anti-insulin antibodies can account for this scenario, we assayed anti-insulin antibodies, which confirmed the diagnosis of autoimmune hypoglycemia due to anti-insulin antibodies.
The prevailing view is that immunoreactive C-peptide levels are not increased in autoimmune hypoglycemia due to anti-insulin antibodies. 9 However, this does not appear to be correct since increased C-peptide levels have been reported in diagnosed patients with anti-insulin antibodies. 1, 6 Unlike most case reports including these two series in non-Asian patients, 1, 6 we assayed both free and total C-peptide levels. We show that unlike in disorders of the b cell accounting for hyperinsulinism, where both proinsulin and C-peptide are elevated, our patient showed an elevated total C-peptide but a normal free C-peptide level. Hence, we can exclude b cell pathology accounting for the elevated total C-peptide level and, by inference, the total proinsulin level and suggest that interference from the anti-insulin antibody complex and/or the M-protein accounts for the total immunoreactive C-peptide and proinsulin levels. Furthermore, we also assayed both free and total insulin levels, and although only 8.6% of the total insulin level was free, unlike free C-peptide, it was still very elevated at 144 µIU/mL and hence clearly sufficient to cause hypoglycemia. In ❚Table 2❚ we summarize the differential diagnosis of endogenous hyperinsulinemic hypoglycemia. 5 Since C-peptide and proinsulin levels were never undetectable, we did not entertain factitious hypoglycemia from exogenous insulin. However, since sulfonylurea ingestion, b cell pathology (usually insulinoma), and autoimmune hypoglycemia syndromes can account for this picture, we suggest that in addition to the sulfonylurea screen and imaging measurement of anti-insulin antibodies and free C-peptide levels, if total C-peptide is elevated, this can be a very useful adjunctive test. For completeness with the consistent clinical picture, anti-insulin receptor antibodies can be useful in the correct clinical setting. While we could not obtain either a free C-peptide or free proinsulin level by any reference laboratory in the United States, we describe in this report a simple and practical assay for quantitating free C-peptide and free insulin following PEG precipitation. This method can also be used to measure the free proinsulin level but was not done due to limited sample and resources.
Conclusion
We report on a white man with symptomatic hypoglycemia due to anti-insulin antibodies and show by further testing that the anti-insulin antibody and/or M-protein can result in major interference in these immunoassays, misleading the clinician to a diagnosis of insulinoma. We suggest that PEG precipitation can prove very useful for measuring free C-peptide, as illustrated in this patient, as well as other elevated immunoreactive hormones such as insulin and proinsulin.
